RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.

The goal of this randomized clinical trial is to compare relapse remitting multiple sclerosis (RRMS) patients treated by ocrelizumab or by rituximab followed for 2 years. The main question it aims to answer is : • to demonstrate the non-inferiority of rituximab versus ocrelizumab in active relapsing MS patients on the % of patients without disease activity at 2 years. During the 2 years, the study includes 6 follow-up visits and the completion of various health and quality of life questionnaires. The protocol visits follow the usual schedule of treatment infusions for the disease (at initiation of treatment, 15 days after, and then every 6 months). Two comparison groups: Researchers will compare rituximab treated patients versus ocrelizumab treated patients to see the % of patients without disease activity at 2 years.

NCT Number	NCT05758831
Lead Sponsor	Rennes University Hospital
Conditions	Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis
Enrollment	386 participants
Start Date	2023-06-01
Primary Completion	2030-03-31 (estimated)
Study Completion	2030-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-02-02